Guidelines for medical treatment of acute Kawasaki disease: Report of the Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery (2012 revised version)

Pediatrics International

Volumn 56, Issue 2, 2014, Pages 135-158

  Saji, Tsutomu ^a  

^a TOHO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ALTEPLASE; ANTICOAGULANT AGENT; ASPARTATE AMINOTRANSFERASE; CLOPIDOGREL; CORONARY VASODILATING AGENT; CYCLOSPORIN A; DIPYRIDAMOLE; FIBRINOLYTIC AGENT; FLURBIPROFEN; HEPARIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INFLIXIMAB; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; METHYLPREDNISOLONE; MONTEPLASE; PREDNISOLONE; STEROID; SULFANILAMIDE; TICLOPIDINE; ULINASTATIN; UROKINASE; WARFARIN; ANTITHROMBOCYTIC AGENT; GLUCOCORTICOID; GLYCOPROTEIN; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ACUTE KIDNEY FAILURE; ADRENAL CORTEX INSUFFICIENCY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALGORITHM; ANAPHYLACTIC SHOCK; ANAPHYLAXIS; ASEPTIC MENINGITIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHMA; BACTERIAL PNEUMONIA; BLEEDING; BONE MARROW SUPPRESSION; CENTRAL SEROUS RETINOPATHY; CHILL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; CYANOSIS; DIABETES MELLITUS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; EOSINOPHILIA; EPIGASTRIC DISCOMFORT; EPISTAXIS; ESOPHAGITIS; EVIDENCE BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GINGIVA BLEEDING; GLAUCOMA; HAIR LOSS; HEART ARRHYTHMIA; HEART FAILURE; HEART RUPTURE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HEMATEMESIS; HEMOLYTIC ANEMIA; HEPATITIS B; HEPATITIS C; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPOMAGNESEMIA; HYPOTENSION; HYPOTHERMIA; HYPOVOLEMIA; INFECTION; INJECTION SITE PAIN; INTRACRANIAL HYPERTENSION; JAUNDICE; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; LOSS OF APPETITE; LUNG EDEMA; MALIGNANT NEOPLASTIC DISEASE; MEDICAL INFORMATION; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYOPATHY; OSTEOPOROSIS; PANCREATITIS; PERTHES DISEASE; PLASMAPHERESIS; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; SEIZURE; SEPSIS; SHIVERING; SHOCK; SIDE EFFECT; SINUS BRADYCARDIA; SUBCAPSULAR CATARACT; THROMBOCYTOPENIA; THROMBOSIS; TUBERCULOSIS; URTICARIA; CHILD;

ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; CHILD; GLUCOCORTICOIDS; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; METHYLPREDNISOLONE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PLATELET AGGREGATION INHIBITORS; PREDNISOLONE;

EID: 84910648235     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/ped.12317     Document Type: Review

References (120)

1. Nakamura Y, Yashiro M, Uehara R, et al. Epidemiologic features of Kawasaki disease in Japan: Results of the 2009-2010 nationwide survey. J. Epidemiol. 2012; 22: 216-221.
2. Ayusawa M, Sonobe T, Uemura S, et al. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr. Int. 2005; 47: 232-234.
3. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013; 65: 1-11.
4. Naoe S, Takahashi K, Masuda H, et al. Kawasaki disease. With particular emphasis on arterial lesions. Acta Pathol. Jpn 1991; 41: 785-797.
5. Asai T,. Diagnosis and prognosis of coronary artery lesions in Kawasaki disease. Coronary angiography and the conditions for its application (a score chart). Nihon Rinsho. 1983; 41: 2080-2085 (in Japanese).
6. Iwasa M, Sugiyama K, Ando T, Nomura H, Katoh T, Wada Y,. Selection of high-risk children for immunoglobulin therapy in Kawasaki disease. Prog. Clin. Biol. Res. 1987; 250: 543-544.
7. Harada K,. Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr Jpn. 1991; 33: 805-810.
8. Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006; 113: 2606-2612.
9. Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J. Pediatr. 2006; 149: 237-240.
10. Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of nonresponsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur. J. Pediatr. 2007; 166: 131-137.
11. Okada K, Hara J, Maki I, et al. Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease. Eur. J. Pediatr. 2009; 168: 181-185.
12. Ogata S, Ogihara Y, Honda T, et al. Corticosteroid pulse combination therapy for refractory Kawasaki disease: A randomized trial. Pediatrics 2012; 129: e17-23.
13. Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease: A prospective, randomised, open, blinded-endpoint trial. Lancet 2012; 379: 1613-1620.
14. Kato H, Koike S, Yokoyama T,. Kawasaki disease: Effect of treatment on coronary artery involvement. Pediatrics 1979; 63: 175-179.
15. Furusho K, Kamiya T, Nakano H, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984; 2: 1055-1058.
16. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N. Engl. J. Med. 1986; 315: 341-347.
17. Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N. Engl. J. Med. 1991; 324: 1633-1639.
18. Oates-Whitehead RM, Baumer JH, Haines L, et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst. Rev. 2003; (4): CD004000.
19. Leung DY, Cotran RS, Kurt-Jones E, et al. Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet 1989; 2: 1298-1302.
20. Abe J, Jibiki T, Noma S, et al. Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease. J. Immunol. 2005; 174: 5837-5845.
21. Terai M, Jibiki T, Harada A, et al. Dramatic decrease of circulating levels of monocyte chemoattractant protein-1 in Kawasaki disease after gamma globulin treatment. J. Leukoc. Biol. 1999; 65: 566-572.
22. Bayary J, Dasgupta S, Misra N, et al. Intravenous immunoglobulin in autoimmune disorders; an insight into the immunoregulatory mechanisms. Int. Immunopharmacol. 2006; 6: 528-534.
23. Tse SM, Silverman ED, McCrindle BW, et al. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease. J. Pediatr. 2002; 140: 450-455.
24. Uehara R, Yashiro M, Oki I, et al. Re-treatment regimens for acute stage of Kawasaki disease patients who failed to respond to initial intravenous immunoglobulin therapy: Analysis from the 17th nationwide survey. Pediatr. Int. 2007; 49: 427-430.
25. Boyce TG, Spearman P,. Acute aseptic meningitis secondary to intravenous immunoglobulin in a patient with Kawasaki syndrome. Pediatr. Infect. Dis. J. 1998; 17: 1054-1056.
26. Nakagawa M, Watanabe N, Okuno M, et al. Severe hemolytic anemia following high-dose intravenous immunoglobulin administration in a patient with Kawasaki disease. Am. J. Hematol. 2000; 63: 160-161.
27. Bonilla FA,. Intravenous immunoglobulin: Adverse reactions and management. J. Allergy Clin. Immunol. 2008; 122: 1238-1239.
28. Nimmerjahan F, Ravetch J,. Anti-inflammatory actions of intravenous immunoglobulin. Annu. Rev. Immunol. 2008; 26: 513-533.
29. Saji T, Sonobe T, Hamaoka K, et al. Safety and effectiveness of intravenous immunoglobulin preparations for the treatment of Kawasaki disease. Prog. Med. 2012; 32: 1369-1375.
30. Stahn C, Buttgereit F,. Genomic and nongenomic effects of glucocorticoids. Nat. Clin. Pract. Rheumatol. 2008; 4: 525-533.
31. Sinha A, Bagga A,. Pulse steroid therapy. Indian J. Pediatr. 2008; 75: 1057-1066.
32. Miura M, Kohno K, Ohki H, et al. Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. Eur. J. Pediatr. 2008; 167: 1119-1123.
33. Ogata S, Ogihara Y, Nomoto K, et al. Clinical score and transcript abundance patterns identify Kawasaki disease patients who may benefit from addition of methylprednisolone. Pediatr. Res. 2009; 66: 577-584.
34. Newburger JW, Sleeper LA, McCrindle BW, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N. Engl. J. Med. 2007; 356: 663-675.
35. Wright DA, Newburger JW, Baker A, et al. Treatment of immune globulin-resistant Kawasaki disease with pulsed dose of corticosteroids. J. Pediatr. 1996; 128: 146-149.
36. Hashino K, Ishii M, Iemura M, et al. Re-treatment for immune globulin-resistant Kawasaki disease: A comparative study of additional immune globulin and steroid pulse therapy. Pediatr. Int. 2001; 43: 211-217.
37. Ogata S, Bando Y, Kimura S, et al. The strategy of immune globulin resistant Kawasaki disease: A comparative study of additional immune globulin and steroid pulse therapy. J. Cardiol. 2009; 53: 15-19.
38. Furukawa T, Kishiro M, Akimoto K, et al. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch. Dis. Child. 2008; 93: 142-146.
39. Miura M, Tamame T, Naganuma T, et al. Steroid pulse therapy for Kawasaki disease unresponsive to additional immunoglobulin therapy. Paediatr Child Health. 2011; 16: 479-484.
40. Zhu BH, Lv HT, Sun L, et al. A meta-analysis on the effect of corticosteroid therapy in Kawasaki disease. Eur. J. Pediatr. 2012; 171: 571-578.
41. Miura M, Ohki H, Yoshiba S, et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Arch. Dis. Child. 2005; 90: 1096-1097.
42. Okawa S, Kawasaki T, Kosaki A, et al. Study of deaths from acute mucocutaneous lymph node syndrome (MCLS). Syonika Shinryo 1975; 38: 608-614 (in Japanese).
43. Kusakawa S, Tatara K,. Research on treatment of acute-stage Kawasaki disease (third report): A prospective study of three treatment options: Aspirin, flurbiprofen, prednisolone+dipyridamole. Nihon Shonika Gakkai Zasshi 1986; 90: 1844-1849 (in Japanese).
44. Shinohara M, Sone K, Tomomasa T, Morikawa A,. Corticosteroids in the treatment of the acute phase of Kawasaki disease. J. Pediatr. 1999; 135: 465-469.
45. Inoue Y, Okada Y, Shinohara M, et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: Clinical course and coronary artery outcome. J. Pediatr. 2006; 149: 336-341.
46. Kobayashi T, Inoue Y, Otani T, et al. Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease. Pediatr. Infect. Dis. J. 2009; 28: 498-502.
47. Hibino K, Ashida M, Iwashima S, et al. A cooperative, multicenter study of treatments for Kawasaki disease. Nihon Shonika Gakkai Zasshi 2008; 112: 1227-1232 (in Japanese).
48. Millar K, Manlhiot C, Yeung RS, Somji Z, McCrindle BW,. Corticosteroid administration for patients with coronary artery aneurysms after Kawasaki disease may be associated with impaired regression. Int. J. Cardiol. 2012; 154: 9-13.
49. Breda L, Del Torto M, De Sanctis S, et al. Biologics in children's autoimmune disorders: Efficacy and safety. Eur. J. Pediatr. 2010; 170: 157-167.
50. Weiss JE, Eberhard A, Chowdhury D, et al. Infliximab as a novel therapy for refractory Kawasaki disease. J. Rheumatol. 2004; 31: 808-810.
51. Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki syndrome. J. Pediatr. 2005; 146: 662-667.
52. Saji T, Kemmotsu Y,. Infliximab for Kawasaki syndrome. J. Pediatr. 2006; 149: 426.
53. Stenbog EV, Windelborg B, Horlyck A, et al. The effect of TNFalpha blockade in complicated, refractory Kawasaki disease. Scand. J. Rheumatol. 2006; 35: 318-321.
54. O'Connor MJ, Saulsbury FT,. Incomplete and atypical Kawasaki disease in a young infant: Severe, recalcitrant disease responsive to infliximab. Clin Pediatr 2007; 46: 345-348.
55. Oishi T, Fujieda M, Shiraishi T, et al. Infliximab treatment for refractory Kawasaki disease with coronary artery aneurysm. Circ. J. 2008; 72: 850-852.
56. Girish M, Subramaniam G,. Infliximab treatment in refractory Kawasaki syndrome. Indian J. Pediatr. 2008; 75: 521-522.
57. Burns JC, Best BM, Mas PD, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J. Pediatr. 2008; 153: 833-838.
58. Brogan RJ, Eleftheriou D, Gnanapragasam J, et al. Infliximab for the treatment of intravenous immunoglobulin resistant Kawasaki disease complicated by coronary artery aneurysms: A case report. Pediatr. Rheumatol. 2009; 7: 1-5.
59. Saji T, Nakagawa N, Ogawa S, et al. Committee Report: Nationwide survey report on the use of the biopharmaceutical biologics infliximab (Remicade) in treating IVIG resistant cases of acute Kawasaki disease: Safety and usefulness. J. Jpn. Soc. Pediatr. Cardiol. Cardiac Surg. 2009; 25: 268-269 (in Japanese).
60. Mori M, Imagawa T, Hara R, et al. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: Report of an open-label case series. J. Rheumatol. 2012; 39: 864-867.
61. Shirley DA, Stephens I,. Primary treatment of incomplete Kawasaki disease with infliximab and methylpredonisolone in a patient with a contraindication to intravenous immune globulin. Pediatr. Infect. Dis. J. 2010; 29: 978-979.
62. Hirono K, Kemmotsu Y, Wittkowski H, et al. Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease. Pediatr. Res. 2009; 65: 696-701.
63. Son MB, Gauvreau K, Ma L, et al. Treatment of Kawasaki disease: Analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics 2009; 124: 1-8.
64. Rowley AH, Shulman ST,. Pathogenesis and management of Kawasaki disease. Expert Rev. Anti Infect. Ther. 2010; 8: 197-203.
65. Hii-Yuen JS, Duong TT, Yeung RSM,. TNF-α is necessary for induction of coronary artery inflammation and aneurysm formation in an animal model of Kawasaki disease. J. Immunol. 2006; 176: 6294-6301.
66. Carter JD, Ladhani A, Ricca LR, et al. A safety assessment of tumor necrosis factor antagonists during pregnancy: A review of the Food and Drug Administration database. J. Rheumatol. 2009; 36: 635-641.
67. Molloy ES, Langford CA, Clark TM, et al. Anti-tumor necrosis factor therapy in patients with refractory Takayasu arteritis: Long-term follow-up. Ann. Rheum. Dis. 2008; 67: 1567-1569.
68. Koh MJ, Tay YK,. An update on Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Curr. Opin. Pediatr. 2009; 21: 505-510.
69. Ruperto N, Lovell DJ, Cuttica R, et al. Pediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007; 56: 3096-3106.
70. Saag KG, Teng GG, Patkar M, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008; 59: 762-784.
71. Horneff G,. Malignancy and tumor necrosis factor inhibitors in juvenile idiopathic arthritis. J. Rheumatol. 2010; 69: 516-526.
72. Diak P, Siegel J, Grenade L, Choi L, Lemery S, McMahon A,. Malignancy in children and tumor necrosis factor-alpha blockers: Forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum. 2010; 62: 2517-2524.
73. Lahdenne P, Wikstrom AM, Aalto K, et al. Prevention of acute adverse events related to infliximab infusions in pediatric patients. Arthritis Care Res. (Hoboken) 2010; 62: 785-790.
74. Gerloni V, Pontikaki I, Gattinnara M, et al. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Am. Rheum. Dis. 2008; 67: 1145-1152.
75. Ruperto N, Lovell DJ, Cuttica R, et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis: Findings from an open-label treatment extension. Ann. Rheum. Dis. 2010; 69: 718-722.
76. de Rodder L, Rings EH, Damen GM, et al. Infliximab dependency in pediatric Crohn's disease. Long-term follow-up of an unselected cohort. Inflamm. Bowel Dis. 2008; 14: 353-356.
77. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology: Recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. (Hoboken) 2012; 64: 625-639.
78. Harigai M, Mochida S, Koike T, et al. A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosppressive therapy. Mod. Rheumatol. 2014; 24: 1-7.
79. Saji T,. Therapy with the protein-degradation enzyme blocker Ulinastatin. Shonika Shinryo 2008; 66: 343-348 (in Japanese).
80. Aosasa S, Ono S, Mochizuki H, et al. Mechanism of the inhibitory protease inhibitor on tumor necrosis factor alpha production of monocytes. Shock 2001; 15: 101-105.
81. Aosasa S, Ono S, Seki S, et al. Inhibitory effect of protease inhibitor on endothelial cell activation. J. Surg. Res. 1998; 80: 182-187.
82. Zaitsu M, Hamasaki Y, Tashiro K, et al. Ulinastatin, an elastase inhibitor, inhibits the increased mRNA expression of prostaglandin H2 synthase-type 2 in Kawasaki disease. J. Infect. Dis. 2000; 181: 1101-1109.
83. Nakatani K, Takeshita S, Tsujimoto H, et al. Inhibitory effect of serine protease inhibitors on neutrophil-mediated endothelial cell injury. J. Leukoc. Biol. 2001; 69: 241-247.
84. Okada M, Nakai S, Ookado K, et al. The results of ulinastatin and antithrombin III medications administered to severe Kawasaki disease patients displaying shock symptoms. Nihon Shonika Gakkai Zasshi. 1993; 97: 43-48 (in Japanese).
85. Saji T, Ozawa Y, Takeuchi M, et al. Treating Kawasaki disease with ulinastatin. Syonika 1999; 40: 1049-1054 (in Japanese).
86. Nakatani K, Takeshita S, Kawamura Y,. Please tell me the mechanism of action of ulinastatin during acute-stage Kawasaki disease and the clinical results obtained with it. Syouni Naika 2003; 9: 1578-1581 (in Japanese).
87. Kanai T, Ishiwata T, Kobayashi T, et al. Ulinastatin, a urinary trypsin inhibitor, for the initial treatment of patients with Kawasaki disease: As retrospective study. Circulation 2011; 124: 2822-2828.
88. Onouchi Y, Gunji T, Burns JC, et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat. Genet. 2008; 40: 35-42.
89. Raman V, Kim J, Sharkey A, et al. Response of refractory Kawasaki disease to pulse-steroid and cyclosporine A therapy. Pediatr. Infect. Dis. J. 2001; 20: 635-637.
90. Suzuki H, Terai M, Hamada H, et al. Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin. Pediatr. Infect. Dis. J. 2011; 30: 871-876.
91. Tremolet AH, Pancoast P, Franco A, et al. Calcineurin inhibitor treatment of IVIG-resistant Kawasaki disease. J. Pediatr. 2012; 161: 506-512.
92. Amazaki Y,. The calcineurin and NFAT system and its inhibition. Jpn J. Clin. Immunol. 2010; 33: 249-261.
93. Lee TJ, Kim KH, Chun JK, Kim DS,. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease. Yonsei Med. J. 2008; 49: 714-718.
94. Joh K,. Effects of plasma exchange in Kawasaki disease. In:, Oda T, (ed). Therapeutic Plasmapheresis (IV). Schattauer, New York, 1985; 519-524.
95. Takagi N, Kihara M, Yamaguchi S, et al. Plasma exchange in Kawasaki disease. Lancet 1995; 346: 1307.
96. Villain E, Kachaner J, Sidi D, et al. Trial of prevention of coronary aneurysm in Kawasaki's disease using plasma exchange or infusion of immunoglobulins. Arch. Fr. Pediatr. 1987; 44: 79-83 (in French).
97. Imagawa T, Mori M, Miyamae T, et al. Plasma exchange for refractory Kawasaki disease. Eur. J. Pediatr. 2004; 163: 263-264.
98. Mori M, Imagawa T, Katakura S, et al. Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma-globulin. Mod. Rheumatol. 2004; 14: 43-47.
99. Hokosaki T, Mori M, Nishizawa T, et al. Long-term efficacy of plasma exchange treatment for refractory Kawasaki disease. Pediatr. Int. 2012; 54: 99-103.
100. Japan Apheresis Society Scientific Committee. The present state of apheresis (results of the 2002 survey). Japan Apher. Soc. 2005; 54: 99-103.
101. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease. A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004; 110: 2747-2771.
102. Durongpisitkul K, Gururaj VJ, Park JM, et al. The prevention of coronary artery aneurysm in Kawasaki disease: A meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995; 96: 1057-1061.
103. Terai M, Shulman ST,. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J. Pediatr. 1997; 131: 888-893.
104. Li JS, Yow E, Berezny KY, et al. Dosing of clopidogrel for platelet inhibition in infants and young children. Primary results of the platelet inhibition in children on Clopidogrel (PICOLO) trial. Circulation 2008; 117: 553-559.
105. Takahashi H, Wilkinson GR, Nutescu EA, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet. Genomics 2006; 16: 101-110.
106. JCS Joint Working Group. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2008)-digest version. Circ. J. 2010; 74: 1989-2020.
107. Ohkubo T, Fukazawa R, Ikegami E, et al. Reduced shear stress and disturbed flow may lead to coronary aneurysm and thrombus formations. Pediatr. Int. 2007; 49: 1-7.
108. Hanania G,. Management of anticoagulants during pregnancy. Heart 2001; 86: 125-126.
109. Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: A systematic overview. JAMA 2004; 292: 89-96.
110. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006; 113: 2363-2372.
111. Shiraishi J, Sawada T, Tatsumi T, et al. Acute myocardial infarction due to a regressed giant coronary aneurysm as possible sequela of Kawasaki disease. J. Invasive Cardiol. 2001; 13: 569-572.
112. Kato H, Inoue O, Ichinose E, et al. Intracoronary urokinase in Kawasaki disease: Treatment and prevention of myocardial infarction. Acta Paediatr. Jpn. 1991; 33: 27-35.
113. Tsubata S, Ichida F, Hamamichi Y, Miyazaki A, Hashimoto I, Okada T,. Successful thrombolytic therapy using tissue-type plasminogen activator in Kawasaki disease. Pediatr. Cardiol. 1995; 16: 186-189.
114. Onouchi Z, Hamaoka K, Sakata K, et al. Long-term changes in coronary artery aneurysms in patients with Kawasaki disease: Comparison of therapeutic regimens. Circ. J. 2005; 69: 265-272.
115. Ito A, Fukumoto Y, Shimokawa H,. Changing characteristics of patients with vasospastic angina in the era of new calcium channel blockers. J. Cardiovasc. Pharmacol. 2004; 44: 480-485.
116. Bruns LA, Chrisant MK, Lamour JM, et al. Carvedilol as therapy in pediatric heart failure: An initial multicenter experience. J. Pediatr. 2001; 138: 505-511.
117. Kimura E, Kishida H,. Treatment of variant angina with drugs: A survey of 11 cardiology institutes in Japan. Circulation 1981; 63: 844-848.
118. Tsuda E, Yasuda T, Naito H,. Vasospastic angina in Kawasaki disease. J. Cardiol. 2008; 51: 65-69.
119. Aizawa T, Ogasawara K, Kato K,. Effects of nicorandil on coronary circulation in patients with ischemic heart disease: Comparison with nitroglycerin. J. Cardiovasc. Pharmacol. 1987; 10: S123-129.
120. Saji T, Ayusawa M, Miura M, et al. Guidelines for medical treatment of acute Kawasaki disease: Report of the Research Committee of the Japanese Society of pediatric cardiology and cardiac surgery (2012 revised version). Jpn. Soc. Pediatr. Cardiol. Cardiac Surg. 2012; 28 (Suppl. 3): 1-s28.